Amneal Q3 net revenue $620M (+14% YoY); adjusted EBITDA $154M (+22%); guidance raised

Amneal Pharmaceuticals, Inc.

2023-Q3 EPS reported $0.09 revenue$1,776,626,000

Net revenue $620M (+14% YoY); GAAP net income $10M ($0.06 EPS) vs loss $0.02 in Q3 2022.
Adjusted net income $60M; adjusted EBITDA $154M (+22%); adjusted EPS $0.19 vs $0.14.
Generics revenue +12%, AvKARE +25%, Specialty +9%; all segments contributed to growth.
FY2023 guidance affirmed after previously being raised; on track to launch 40+ generics; IPX203 on track for 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amneal Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: revenue $620 million, net income $10 million, EPS $0.06.

Period: third quarter ended September 30, 2023
Revenue: $620 million
Net income: $10 million
EPS: $0.06
Result: reported results

Exact text from the filing

the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS ‒ Q3 2023 Net Revenue of $620 million; GAAP Net Income of $10 million; Diluted EPS of $0.06 ‒ ‒ Q3 2023 Adjusted Net Income (1) of $60 million; Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.19 ‒

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-23-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.